288 related articles for article (PubMed ID: 14567092)
1. [Serum aminoterminal peptide of type III procollagen (PIIINP) and transforming growth factor-beta1 (TGF-beta1) levels in patients with chronic hepatitis B and C].
Marek B; Kajdaniuk D; Janczewska-Kazek E; Beniowski M; Swietochowska E; Kos-Kudła B; Ostrowska Z; Mazurek U; Wilczok T; Nowak M; Siemińska L; Borgiel-Marek H; Strzyzewski A; Januła A; Sierek K; Niedzielski Z
Pol Arch Med Wewn; 2003 Jun; 109(6):603-8. PubMed ID: 14567092
[TBL] [Abstract][Full Text] [Related]
2. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis.
Flisiak R; Maxwell P; Prokopowicz D; Timms PM; Panasiuk A
Hepatogastroenterology; 2002; 49(47):1369-72. PubMed ID: 12239944
[TBL] [Abstract][Full Text] [Related]
3. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis.
Murawaki Y; Nishimura Y; Ikuta Y; Idobe Y; Kitamura Y; Kawasaki H
J Gastroenterol Hepatol; 1998 Jul; 13(7):680-4. PubMed ID: 9715417
[TBL] [Abstract][Full Text] [Related]
4. [Role of transforming growth factor beta1 (TGF-beta1) in the pathogenesis and clinical course of chronic hepatitis in children].
Liberek A; Marek A; Kmieć Z; Kartanowicz D; Szlagatys-Sidorkiewicz A; Łuczak G; Wierzbicki PM; Stanisławowski M; Wierzbicki M; Marek K; Liberek T; Sikorska-Wiśniewska G; Góra-Gebka M; Wegrzyn G; Kamińska B
Med Wieku Rozwoj; 2009; 13(3):163-70. PubMed ID: 20081261
[TBL] [Abstract][Full Text] [Related]
5. Urinary transforming growth factor beta1 levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Tsai JH
Hepatology; 1997 May; 25(5):1141-6. PubMed ID: 9141431
[TBL] [Abstract][Full Text] [Related]
6. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis.
Walsh KM; Fletcher A; MacSween RN; Morris AJ
Eur J Gastroenterol Hepatol; 1999 Aug; 11(8):827-31. PubMed ID: 10514112
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
8. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.
Valva P; Casciato P; Diaz Carrasco JM; Gadano A; Galdame O; Galoppo MC; Mullen E; De Matteo E; Preciado MV
PLoS One; 2011; 6(8):e23218. PubMed ID: 21858035
[TBL] [Abstract][Full Text] [Related]
9. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta.
Kanzler S; Baumann M; Schirmacher P; Dries V; Bayer E; Gerken G; Dienes HP; Lohse AW
J Viral Hepat; 2001 Nov; 8(6):430-7. PubMed ID: 11703574
[TBL] [Abstract][Full Text] [Related]
10. [Quantitative assessment of mRNA TGF-beta1 in liver tissue in connection with serum mean daily level of TGF-1 in chronic hepatitis B patient].
Marek B; Kajdaniuk D; Mazurek U; Janczewska-Kazek E; Strzałka B; Beniowski M; Kos-Kudła B; Kajdaniuk J; Niedziołka D; Ostrowska Z; Borgiel-Marek H; Siemińiska L; Nowak M; Pakuła D; Gatnar A; Gnot R; Filipczyk P
Pol Arch Med Wewn; 2005 Aug; 114(2):738-45. PubMed ID: 16808311
[TBL] [Abstract][Full Text] [Related]
11. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B.
Lebensztejn DM; Sobaniec-Lotowska M; Kaczmarski M; Werpachowska I; Sienkiewicz J
Hepatogastroenterology; 2004; 51(55):229-33. PubMed ID: 15011870
[TBL] [Abstract][Full Text] [Related]
12. Fibrosis markers, hip fracture risk, and bone density in older adults.
Barzilay JI; Bůžková P; Kizer JR; Djoussé L; Ix JH; Fink HA; Siscovick DS; Cauley JA; Mukamal KJ
Osteoporos Int; 2016 Feb; 27(2):815-20. PubMed ID: 26267013
[TBL] [Abstract][Full Text] [Related]
13. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
14. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis.
Kamal SM; Turner B; He Q; Rasenack J; Bianchi L; Al Tawil A; Nooman A; Massoud M; Koziel MJ; Afdhal NH
Hepatology; 2006 Apr; 43(4):771-9. PubMed ID: 16557547
[TBL] [Abstract][Full Text] [Related]
15. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
[TBL] [Abstract][Full Text] [Related]
16. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
Lin DY; Chu CM; Sheen IS; Liaw YF
Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic value of five serum markers for liver fibrosis].
Luo R; Yang S; Xie J; Zhao Z; He Y; Yao J
Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):148-50. PubMed ID: 11412388
[TBL] [Abstract][Full Text] [Related]
18. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
Castilla A; Prieto J; Fausto N
N Engl J Med; 1991 Apr; 324(14):933-40. PubMed ID: 1900574
[TBL] [Abstract][Full Text] [Related]
20. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
